Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;13(4):308-13.
doi: 10.2174/138920212800793294.

Epigenome-Wide Association Studies (EWAS) in Cancer

Affiliations

Epigenome-Wide Association Studies (EWAS) in Cancer

Mukesh Verma. Curr Genomics. 2012 Jun.

Abstract

After completion of the human genome, genome-wide association studies were conducted to identify single nucleotide polymorphisms (SNPs) associated with cancer initiation and progression. Most of the studies identified SNPs that were located outside the coding region, and the odds ratios were too low to implement in clinical practice. Although the genome gives information about genome sequence and structure, the human epigenome provides functional aspects of the genome. Epigenome-wide association studies (EWAS) provide an opportunity to identify genome-wide epigenetic variants that are associated with cancer. However, there are problems and issues in implementing EWAS to establish an association between epigenetic profiles and cancer. Few challenges include selection and handling of samples, choice of population and sample size, accurate measurement of exposure, integrating data, and insufficient information about the role of repeat sequences. The current status of EWAS, challenges in the field, and their potential solutions are discussed in this article.

Keywords: Acetylation; biomarker; chromatin; environmental mutagens; epidemiology; epigenetics; histone; histone acetyl transferase (HAT); histone code; histone deacetylase (HDAC); imprinting; methyl transferase; methylation; mutagens; risk assessment; screening..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Challenges in EWAS.

Similar articles

Cited by

References

    1. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2007;358:1148–1159. - PubMed
    1. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36. - PMC - PubMed
    1. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc. Natl. Acad. Sci. USA. 2010;107:16228–16233. - PMC - PubMed
    1. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009;10:399–416. - PMC - PubMed
    1. Hede K. Imprinting may provide cancer prevention tools. J. Natl. Cancer Inst. 2007;99:424–426. - PubMed

LinkOut - more resources